RVMDW
Revolution Medicines, Inc. Warrant
NASDAQ · Healthcare · Biotechnology · US
$11.89
−0.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 11.6M | 35.4M |
| Cost of Revenue | 9.2M | 16.6M | — | — | — |
| Gross Profit | (9.2M) | (16.6M) | — | 11.6M | 35.4M |
| Operating Expenses | |||||
| R&D Expense | 1.3B | 978.7M | 592.2M | 423.1M | 253.1M |
| SG&A Expense | 328.5M | 187.1M | 97.3M | 75.6M | 40.6M |
| General & Admin Expense | 328.5M | 187.1M | 97.3M | 75.6M | 40.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (4.5M) | — | — | — | — |
| Total Operating Expenses | 1.6B | 1.2B | 689.5M | 498.8M | 293.7M |
| Cost and Expenses | 1.6B | 1.2B | 689.5M | 498.8M | 293.7M |
| Operating Income (EBIT) | (1.6B) | (1.2B) | (689.5M) | (487.2M) | (258.3M) |
| Non-Operating | |||||
| Interest Income | 98.5M | 90.7M | 86.9M | 47.5M | 9.2M |
| Interest Expense | 59.3M | 24.2M | — | 303.0K | — |
| Net Interest Income | 39.1M | 66.5M | 86.9M | 47.2M | 9.2M |
| Other Non-Op Income/Expense | (141.0M) | 51.1M | 88.7M | 47.3M | 9.2M |
| Non-Operating Income (excl Interest) | 81.7M | (75.3M) | (88.7M) | (47.6M) | (9.2M) |
| EBT (Pre-Tax Income) | (1.8B) | (1.1B) | (600.8M) | (439.9M) | (249.1M) |
| Income Tax Expense | — | — | (753.0K) | (3.5M) | (420.0K) |
| Bottom Line | |||||
| Net Income | (1.8B) | (1.1B) | (600.1M) | (436.4M) | (248.7M) |
| Earnings from Cont. Ops | (1.8B) | (1.1B) | (600.1M) | (436.4M) | (248.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.8B) | (1.1B) | (600.1M) | (436.4M) | (248.7M) |
| Per Share | |||||
| Basic EPS | ($8.86) | ($5.95) | ($3.58) | ($3.86) | ($3.08) |
| Diluted EPS | ($8.86) | ($5.95) | ($3.58) | ($3.86) | ($3.08) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.10 | $0.44 |
| Shares | |||||
| Basic Shares Outstanding | 210.9M | 190.1M | 167.7M | 113.1M | 80.6M |
| Diluted Shares Outstanding | 210.9M | 190.1M | 167.7M | 113.1M | 80.6M |
| Profitability Metrics | |||||
| EBITDA | (1.7B) | (1.1B) | (589.0M) | (430.3M) | (239.5M) |
| D&A | 13.6M | 16.6M | 11.8M | 9.3M | 9.7M |
| EBIT | (1.7B) | (1.1B) | (600.8M) | (439.6M) | (249.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026